TASHKENT, Apr 25 (PRIME) -- Russian pharmaceutical company Pharmasyntez plans to start building a U.S. $30 million anti-tumor medicine plant in Uzbekistan until the end of 2022, Yury Petrosyan, the company’s director for exports to the CIS countries, told PRIME on Monday.
“We estimate our investment at up to $30 million. We are finalizing some figures right now, and I think that we will start (construction) until the end of the year,” Petrosyan said.
Uzbekistan is a strategically important region for Russia and Pharmasyntez, so the company plans to remain in the country for a long time, he added.
Uzbekistan’s Agency on Development of Pharmaceutical Industry Director Sardor Kariyev said that the plant will strengthen Pharmasyntez’ presence not only in Uzbekistan, but in the neighboring countries as well.
End %%md/jst%%
|
|
